Tanya Lewis - Medical Marketing and Media (h/t @bradloncar)
On AEGR Juxtapid (lomitapide) and SNY ISIS Kynamro (mipomersen) in homozygous familial hypercholesterolemia.
Gilead Sciences Building on HIV, Becoming Cancer [and inflammation] Drug Force
Luke Timmerman (Xconomy)
Novartis, Gleevec, and Indian patents? An odd trifecta for a big news story, here are some details from various perspectives...
Novartis press release
New York Time article
In the Pipeline blog (Derek Lowe)
SEC’s New Social Media Guidance: Sensible, Fair, Inevitable
Brad Loncar (Xconomy)
Myths In The Pricing Of New Drugs
John LaMattina (Forbes)
Biosimilars are not similar enough: a proposal for true "biogenerics"
Drug Baron blog
Calls for mandatory licensing of production info after an exclusivity period as alternative to current biosimilar pathways.
Fewer ODAC Meetings? It's not your imagination!
Peggy Eastman (Oncology Times) with comments from Richard Pazdur
Leading Health-care Organizations Issue Guideline Recommendations for Molecular Testing and Targeted Therapies
The ASCO Post
New recommendation: ALL advanced lung adenocarcinoma patients should be screened for EGFR and ALK mutations.